The Cardiac Risk Prediction Array utilizes Biochip Array Technology to offer simultaneous genotyping of 19 SNPs for a reliable CHD risk assessment. Combining such genotype information with common risk factors could allow individuals to be more accurately classified and preventative therapies and lifestyle advice can be targeted to those who require it most. Randox has developed a rapid array which will allow all 18 SNPs to be genotyped simultaneously. Firstly, a multiplex PCR reaction is performed, where the products amplified correspond to the genotype of the patient sample. The PCR products are then hybridized onto the biochip array and imaged using the Evidence Investigator analyzer to identify which PCR products are present. Thus a patient sample can be genotyped within one day. The g...Read more
Receive your quote directly from Randox Laboratories Ltd..